TYGACIL has proven efficacy in clinical trials in complicated skin and skin structure infections. TYGACIL also provides an expanded broad spectrum of antimicrobial activity against gram positives, gram negatives, anaerobes, and methicillin-resistant Staphylococcus aureus.